DE69400799D1 - Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen - Google Patents

Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen

Info

Publication number
DE69400799D1
DE69400799D1 DE69400799T DE69400799T DE69400799D1 DE 69400799 D1 DE69400799 D1 DE 69400799D1 DE 69400799 T DE69400799 T DE 69400799T DE 69400799 T DE69400799 T DE 69400799T DE 69400799 D1 DE69400799 D1 DE 69400799D1
Authority
DE
Germany
Prior art keywords
parkinson
pct
treatment
riluzol
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69400799T
Other languages
English (en)
Other versions
DE69400799T2 (de
Inventor
Alain Boireau
Adam Doble
Pierre Dubedat
Erik Louvel
Mireille Meunier
Jean-Marie Miquet
Jean-Marie Stutzmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Publication of DE69400799D1 publication Critical patent/DE69400799D1/de
Application granted granted Critical
Publication of DE69400799T2 publication Critical patent/DE69400799T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69400799T 1993-01-07 1994-01-03 Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen Expired - Lifetime DE69400799T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9300074A FR2700117B1 (fr) 1993-01-07 1993-01-07 Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
PCT/FR1994/000003 WO1994015601A1 (fr) 1993-01-07 1994-01-03 Application du riluzole dans le traitement de la maladie de parkinson et des syndromes parkinsoniens

Publications (2)

Publication Number Publication Date
DE69400799D1 true DE69400799D1 (de) 1996-11-28
DE69400799T2 DE69400799T2 (de) 1997-03-13

Family

ID=9442862

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69400799T Expired - Lifetime DE69400799T2 (de) 1993-01-07 1994-01-03 Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
DE69400435T Expired - Fee Related DE69400435T2 (de) 1993-01-07 1994-01-03 Verwendung von carbamazepine und oxcarbazepine zur behandlung von parkinson und den parkinson-syndromen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69400435T Expired - Fee Related DE69400435T2 (de) 1993-01-07 1994-01-03 Verwendung von carbamazepine und oxcarbazepine zur behandlung von parkinson und den parkinson-syndromen

Country Status (23)

Country Link
US (2) US5658900A (de)
EP (2) EP0678023B1 (de)
JP (2) JPH08505379A (de)
KR (2) KR100298807B1 (de)
AT (2) ATE144420T1 (de)
AU (3) AU677279B2 (de)
CA (2) CA2153341A1 (de)
CZ (2) CZ284928B6 (de)
DE (2) DE69400799T2 (de)
DK (2) DK0678026T3 (de)
ES (2) ES2091689T3 (de)
FR (1) FR2700117B1 (de)
GR (2) GR3020975T3 (de)
HU (2) HUT72074A (de)
IL (3) IL108285A0 (de)
MX (2) MX9307885A (de)
NO (2) NO307495B1 (de)
PL (2) PL309594A1 (de)
RU (1) RU2221563C2 (de)
SK (2) SK279645B6 (de)
UA (1) UA29464C2 (de)
WO (3) WO1994015610A1 (de)
ZA (3) ZA9426B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6119094A (en) * 1996-02-29 2000-09-12 Electronic Data Systems Corporation Automated system for identifying alternate low-cost travel arrangements
US6417210B1 (en) * 1998-01-09 2002-07-09 Mor-Research Applications Ltd. Treatment of dyskinesias and Parkinson's disease with riluzole and levodopa
AU1780699A (en) * 1998-01-09 1999-07-26 Mor Research Applications Ltd. Treatment of dyskinesias
FR2774592B1 (fr) * 1998-02-06 2000-03-17 Rhone Poulenc Rorer Sa Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet
FR2777781B1 (fr) * 1998-04-24 2004-04-09 Rhone Poulenc Rorer Sa Associations riluzole et l-dopa pour le traitement de la maladie de parkinson
FR2787028B1 (fr) 1998-12-15 2002-10-18 Aventis Pharma Sa Utilisation du riluzole dans le traitement des traumatismes acoustiques
US6506378B1 (en) * 1998-12-16 2003-01-14 Arch Development Corporation Vesicular monoamine transporter gene therapy in Parkinson's disease
FR2801793B1 (fr) * 1999-12-01 2003-07-04 Aventis Pharma Sa Association d'une ergoline et de riluzole et son utilisation comme medicament
JP2004526706A (ja) * 2001-02-12 2004-09-02 テバ ファーマシューティカル インダストリーズ リミティド オクスカルバゼピンの新しい結晶形態及びそれらの調製方法
US20050070524A1 (en) * 2003-06-06 2005-03-31 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders
WO2005037276A1 (en) * 2003-10-09 2005-04-28 Aventis Pharma S.A. Use of riluzole for the treatment of essential tremor
CA2471666C (en) * 2004-06-18 2009-10-13 Apotex Pharmachem Inc. An improved process for the preparation of oxcarbazepine and related intermediates
EP1924326B1 (de) 2005-08-25 2016-10-12 Steven Michael Weiss Reduzierung von myokard-schaden und inzidenz von arrhythmien durch verlust, verringerung oder unterbrechung des koronaren blutflusses
US20070248684A1 (en) * 2006-01-31 2007-10-25 Sigal Blau Pharmaceutical formulations of oxcarbazepine and methods for its preparation
AU2006337141A1 (en) * 2006-01-31 2007-08-09 Teva Pharmaceutical Industries Ltd. Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
ES2360423T3 (es) * 2006-04-26 2011-06-03 Supernus Pharmaceuticals, Inc. Preparaciones de liberación controlada de oxcarbazepina que tienen perfil de liberación sigmoidal.
US20110002972A1 (en) * 2007-09-14 2011-01-06 Scil Technology Gmbh Neuroendocrine factors for treatment of degenerative diseases
EP3006024B1 (de) 2009-01-20 2019-03-20 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Benzoesäure oder salzen davon zur verstärkung der wirkung eines neuropharmakons
WO2011017319A1 (en) 2009-08-03 2011-02-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of treating disorders associated with protein polymerization
US9072772B2 (en) 2009-11-05 2015-07-07 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating disorders associated with protein aggregation
US8809617B2 (en) * 2009-11-05 2014-08-19 The University of Pittsburgh—Of the Commonwealth System of Higher Education Automated high-content live animal drug screening using C. elegans
US9463186B2 (en) 2013-04-15 2016-10-11 Northwestern University Treatment for dopaminergic disorders
CN109563024B (zh) 2016-06-13 2023-06-06 心悦生医股份有限公司 苯甲酸锂的共晶及其用途
CN109563018A (zh) 2016-06-13 2019-04-02 心悦生医股份有限公司 苯甲酸钠的共晶及其用途
US11369579B2 (en) 2016-10-24 2022-06-28 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US10336679B2 (en) 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US10322114B2 (en) 2017-07-31 2019-06-18 Above And Beyond Nb, Llc Formulation of a riluzole solution with beta-cyclodextrins
US10098861B1 (en) 2017-10-24 2018-10-16 Syneurx International (Taiwan) Corp. Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof
CA3151459A1 (en) * 2019-09-20 2021-03-25 Ana PEREIRA Controlled release formulations of riluzole and their uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2948718A (en) * 1960-08-09 New n-heterocyclic compounds
CH500196A (de) * 1969-03-10 1970-12-15 Ciba Geigy Ag Verfahren zur Herstellung von neuen Azepinderivaten
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US4431641A (en) * 1980-10-17 1984-02-14 Ciba-Geigy Corporation Pharmaceutical compositions having antiepileptic and antineuralgic action
GB8613183D0 (en) * 1986-05-30 1986-07-02 Wellcome Found Triazine salt
DE4118740A1 (de) * 1991-06-05 1992-12-10 Schering Ag Neue kombinationspraeparate zur behandlung des morbus parkinson
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.

Also Published As

Publication number Publication date
HU9502065D0 (en) 1995-09-28
EP0678023A1 (de) 1995-10-25
WO1994015607A1 (fr) 1994-07-21
HU217136B (hu) 1999-11-29
AU677279B2 (en) 1997-04-17
CZ284928B6 (cs) 1999-04-14
ES2091689T3 (es) 1996-11-01
AU5819094A (en) 1994-08-15
PL309596A1 (en) 1995-10-30
ZA9428B (en) 1994-08-11
ATE144420T1 (de) 1996-11-15
MX9400287A (es) 1994-07-29
HUT72328A (en) 1996-04-29
WO1994015601A1 (fr) 1994-07-21
AU5818994A (en) 1994-08-15
JPH08505379A (ja) 1996-06-11
PL309594A1 (en) 1995-10-30
SK86795A3 (en) 1995-11-08
KR960700054A (ko) 1996-01-19
JPH08505378A (ja) 1996-06-11
FR2700117B1 (fr) 1995-02-03
NO952309L (no) 1995-06-12
SK86695A3 (en) 1996-05-08
RU2221563C2 (ru) 2004-01-20
DK0678026T3 (da) 1996-09-16
NO952309D0 (no) 1995-06-12
NO952310L (no) 1995-06-12
KR960700059A (ko) 1996-01-19
CA2153341A1 (fr) 1994-07-21
DE69400799T2 (de) 1997-03-13
SK279758B6 (sk) 1999-03-12
DK0678023T3 (da) 1996-11-25
JP3120153B2 (ja) 2000-12-25
ZA9426B (en) 1994-08-11
KR100298807B1 (ko) 2001-11-22
DE69400435T2 (de) 1997-03-06
AU5818894A (en) 1994-08-15
ZA9432B (en) 1994-08-11
FR2700117A1 (fr) 1994-07-08
IL108285A0 (en) 1994-04-12
IL108284A0 (en) 1994-04-12
US5658900A (en) 1997-08-19
DE69400435D1 (de) 1996-10-02
GR3020975T3 (en) 1996-12-31
EP0678026B1 (de) 1996-08-28
UA29464C2 (uk) 2000-11-15
ATE141792T1 (de) 1996-09-15
EP0678023B1 (de) 1996-10-23
CZ176595A3 (en) 1995-12-13
HU9502063D0 (en) 1995-09-28
AU684059B2 (en) 1997-12-04
SK279645B6 (sk) 1999-01-11
MX9307885A (es) 1994-07-29
EP0678026A1 (de) 1995-10-25
ES2092890T3 (es) 1996-12-01
US5674885A (en) 1997-10-07
CZ284363B6 (cs) 1998-11-11
NO952310D0 (no) 1995-06-12
CA2153340A1 (fr) 1994-07-21
IL108286A0 (en) 1994-04-12
HUT72074A (en) 1996-03-28
GR3021438T3 (en) 1997-01-31
WO1994015610A1 (fr) 1994-07-21
CA2153340C (fr) 2002-12-17
IL108284A (en) 1999-03-12
NO307495B1 (no) 2000-04-17
CZ176495A3 (en) 1995-12-13

Similar Documents

Publication Publication Date Title
DE69400799D1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
ATE164067T1 (de) Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen
HUP0001913A2 (hu) Pramipexole alkalmazása állandóan mozgó láb szindróma kezelésére szolgáló gyógyszerkészítmények előállítására
ATE143947T1 (de) N-acylpyrrolidine und arzneimittel zur behandlung oder prophylaxe von mit ckk und gastrin in zusammenhang stehenden krankheiten
DE69421705T2 (de) Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen
IL108283A0 (en) Use of riluzole for promoting restoration following radiation

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: AVENTIS PHARMA S.A., ANTONY, FR

8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN

8328 Change in the person/name/address of the agent

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, 80335 MUENC